---
schema_version: "secwatch.filing_event.v1"
accession: "0001404644-25-000044"
form_type: "8-K"
ticker: "NGNE"
cik: "0001404644"
company_name: "Neurogene Inc."
filed_at: "2025-05-09T23:59:59+00:00"
generated_at: "2026-05-22T01:30:32.513137+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Neurogene reports Q1 net loss of $22.6M; cash $292.6M; NGN-401 trial on track

## Summary
- Net loss of $22.6M for Q1 2025 vs $16.9M Q1 2024; R&D expenses rose to $17.8M from $13.5M.
- Cash, equivalents and short-term investments of $292.6M as of March 31, 2025; runway into H2 2027.
- NGN-401 gene therapy for Rett syndrome: registrational trial plan update expected in H1 2025; interim clinical data in H2 2025.
- Enrolling additional participants in Phase 1/2 trial; pediatric cohort (age 4-10, N=8) and older cohort (11+, N=3).
- Peer-reviewed publication in Science Translational Medicine validating EXACT transgene regulation technology.

## SEC filing metadata
- accession: 0001404644-25-000044
- form_type: 8-K
- ticker: NGNE
- cik: 0001404644
- company_name: Neurogene Inc.
- filed_at: 2025-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404644/000140464425000044/0001404644-25-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404644/000140464425000044/ngne-20250509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001404644-25-000044
- JSON: https://secwatch.observer/filing/0001404644-25-000044.json
- Plain text: https://secwatch.observer/filing/0001404644-25-000044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.